Severe toxicity associated with a markedly elevated mycophenolic acid free fraction in a renal transplant recipient

Therapeutic Drug Monitoring

Volumn 26, Issue 4, 2004, Pages 453-455

  Mudge, David W ^a   Atcheson, Bronwyn A ^a,b   Taylor, Paul J ^a,b   Pillans, Peter I ^a,b   Johnson, David W ^a,b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Free drug; Glucuronide; Mycophenolic acid; Protein binding

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; AMPHOTERICIN; BASILIXIMAB; BILIRUBIN; CALCITRIOL; COTRIMOXAZOLE; CREATINE; CYCLOSPORIN A; DILTIAZEM; GLUCURONIDE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RANITIDINE; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; BILE DUCT OBSTRUCTION; CASE REPORT; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG GLUCURONIDATION; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; HEMATEMESIS; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MALE; NAUSEA; PANCYTOPENIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; UREMIA; VOMITING;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TIME FACTORS;

EID: 3342927520     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200408000-00017     Document Type: Article

References (14)

1. Shaw LM, Mick R, Nowak I, et al. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol. 1998;38:268-275.
2. Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German study group on mycophenolate mofetil therapy in pediatric renal transplant recipients. J Am Soc Nephrol. 1998;9:1511-1520.
3. Kaplan B, Meier-Kriesche HU, Friedman G, et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharm. 1999; 39:715-720.
4. Shaw LM, Kaplan B, DeNofrio D, et al. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther Drug Monit. 2000;22:14-19.
5. Nowak J, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem. 1995;41:1011-1017.
6. Willis C, Taylor PJ, Salm P, et al. Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the concentration-time curve in adult renal transplant recipients. Ther Drug Monit. 2000;22:549-554.
7. Johnson AG, Rigby RJ, Taylor PJ, et al. The kinetics of mycophenolic acid and its glucuronide metabolite in adult renal transplant recipients. Clin Pharmacol Ther. 1999;66:492-500.
8. Atcheson BA, Taylor PJ, Mudge DW, et al. Quantification of free mycophenolic acid and its glucuronide metabolite in human plasma by liquid chromatography using mass spectrometric and ultraviolet detection J Chromatogr B. 2004;799:157-163.
9. Kaplan B, Gruber SA, Nallamathou R, et al. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation 1998;65:1127-1129.
10. Shaw LM, Holt DW, Keown P, et al. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther. 1999;21:1632-1652.
11. Cox VC, Ensom MH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit. 2003:25:137-157.
12. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol. 2002;13:759-768.
13. Weber LT, Lamersdorf T, Shipkova M, et al. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. Ther Drug Monit. 1999;21:498-506.
14. Oellerich M, Shipkova M, Schutz E, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German study group on mycophenolate mofetil therapy in pediatric renal transplant recipients. Ther Drug Monit. 2000;22:20-26.